Chemokine Prostate Cancer Biomarkers

Abbreviated Name
Chemokine Prostate Cancer Biomarkers
Lead Investigator
Macoska, Jill — University of Massachusetts Boston
Coordinating Investigator
Macoska, Jill — University of Massachusetts Boston
Involved Investigators

Abstract

STUDY DESIGN 1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers to distinguish between patients at high-risk versus low-risk for harboring prostate malignancies. However, this pilot and feasibility study utilized a very small sample size of 51 patients, which limited the ability of this study to adequately assess certain technical aspects of the ELISA technique and statistical aspects of we propose studies designed assess the robustness (Specific Aim 1) and predictive value (Specific Aim 2) of these markers in a larger study population. 2. ELISA Assays. Serum, plasma, or urine chemokine levels are assessed using 50 ul frozen specimen per sandwich ELISA in duplicate using the appropriate commercially-available capture antibodies, detection antibodies, and standard ELISA reagents (R&D Systems), as we have described previously (15, 17, 18). Measures within each patient group are regarded as biological replicates and permit statistical comparisons between groups. For all ELISAs, a standard curve is generated with the provided standards and utilized to calculate the quantity of chemokine in the sample tested. These assays provide measures of protein concentration with excellent reproducibility, with replicate measures characterized by standard deviations from the mean on the order of <3%.

Aims

SPECIFIC AIMS/DELIVERABLES. In order to test this hypothesis, we will accomplish two Specific Aims: Specific Aim 1. Assess the robustness of serum, plasma, or urine measures of CXCL5 and CXCL12. Specific Aim 2. Determine whether serum, plasma, or urine levels of CXCL5 and CXCL12 provide sufficient predictive value for prostate cancer among men with low (<10ng/ml) total serum PSA.

Analytic Method

The results of these assays will determine whether statistically significant associations between disease status in the prostate (no disease, BPH, PCa with or without concomitant BPH) and serum, plasma, or urine protein levels for CXCL5 and/or CXCL12 are observed among patients with low but detectable serum PSA. If so, then ROC analyses will determine whether the sensitivity and specificity of these protein levels to ‘predict’ disease status are superior to those of PSA or other similarly evaluated biomarkers as reported in the literature. If so, a larger, multiinstitutional study to validate these findings across a broader patient population will be pursued through collaborative efforts within the NCI-sponsored Early Detection Research Network (EDRN) to validate these findings. Conversely, if no statistically significant associations between disease status in the prostate and serum, plasma, or urine protein levels for CXCL5 and/or CXCL12 are observed, then we will conclude that these proteins do not comprise suitable biomarkers for disease status in the prostate, and that further studies are not warranted.

Comments

Aim 1 is completed, Aim 2 is in prcess

Publications

  • No publications available at this time for this protocol.

Biomarkers

  • No biomarkers available at this time for this protocol.

Data Collections

  • No data collections available at this time for this protocol.
Start Date
Oct 1 2009
Estimated Finish Date
Sep 30 2011
Finish Date
Sep 30 2011
Protocol ID
318
Protocol Type
Single
Fields of Research
  • Proteomics
Collaborative Group
Prostate and Urologic Cancers Research Group
Cancer Types
  • Malignant neoplasm of prostate
Phased Status
1

Associated Forms